The 20-F confirms Ryoncil's commercial ramp is real with $115M in first-year sales, and the $125M refinancing removes near-term liquidity risk. The key catalyst to watch is the mid-CY2027 CLBP Phase 3 readout, which could unlock a much larger market. Traders should monitor quarterly revenue growth and any pipeline updates (adult SR-aGvHD, DMD) for sustained momentum.
Drugs in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this 20-F- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $18.18entry
- T+1 · 3mo ago −4.07%α −3.84% · $17.44
- T+5 · 3mo ago −5.72%α −5.99% · $17.14
- T+20 · 8w ago −14.85%α −14.34% · $15.48
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
How similar events traded
Executive Summary
Mesoblast filed its annual 20-F for FY2026, reporting first full-year product revenue of $115.2M from Ryoncil (approved Dec 2024), a net loss of $57.5M, and cash of $102.9M. The company refinanced its debt with a $125M non-dilutive credit line at 8% interest, reducing borrowing costs. The filing confirms commercial launch progress and a strengthened balance sheet, but the company remains unprofitable with accumulated losses of $1.07B and faces ongoing clinical and regulatory risks for pipeline candidates like rexlemestrocel-L (CLBP, CHF). The cross-filing context amplifies the positive revenue trajectory and pipeline milestones (Phase 3 CLBP enrollment complete, adult SR-aGvHD trial started, DMD IND cleared). Overall, the annual report confirms a transition to a commercial-stage biotech with a validated product, but profitability is not yet achieved, warranting a neutral-to-bullish read with moderate impact.
Key Facts
- Ryoncil net revenue was $115.2M for FY2026, the first full year post-FDA approval.
- Net loss for FY2026 was $57.5M; accumulated deficit reached $1,068.4M.
- Cash and cash equivalents were $102.9M as of June 30, 2026.
- Entered a $125M five-year non-dilutive credit-line facility in Dec 2025, secured by TEMCELL royalties, at 8% fixed interest, used to extinguish Oaktree and NovaQuest debt.
- Net cash used in operating activities was $43.8M for FY2026.
- Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain enrolled target of 300 patients; top-line results expected mid-CY2027.
- Adult SR-aGvHD label extension trial for Ryoncil commenced; IND cleared for Duchenne muscular dystrophy.
- BLA filing number received for rexlemestrocel-L in LVAD patients; CAR technology license acquired.
Financial Impact
First full-year product revenue of $115.2M from Ryoncil; net loss of $57.5M; $102.9M cash; $125M new credit facility at 8% interest reduces debt cost.
Risk Factors
- Company remains unprofitable with $1.07B accumulated deficit; profitability timeline uncertain.
- Pipeline candidates (rexlemestrocel-L for CLBP, CHF) face binary Phase 3 readout risk; failure would reset valuation.
- Reliance on single approved product (Ryoncil) for near-term revenue; any commercial setback would be material.
- Foreign exchange risk from AUD/USD exposure on debt and operations.
- Regulatory risks for label extensions and new indications; FDA may require additional trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001345099-26-000081 |
| Document: 0001345099-26-000081-index.html | 0001345099-26-000081 |
| Document: 0001345099-26-000081.txt | 0001345099-26-000081 |
Track record
25 reports on MESO
7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Viewing Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers